GeneDx HoldingsWGS +1.67%60 EV-to-FCF is -72.26 as of Jun. 28, 2026. GuruFocus rates WGS with a GF Score™ of 60/100 and a GF Value™ of $71.20 (Fairly Valued). The stock has 3 warning signs investors should review. Among 97 Medical Diagnostics & Research companies, GeneDx Holdings ranks worse than 1030926.8% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, GeneDx Holdings's Enterprise Value is $2,070.3 Mil.
GeneDx Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-28.7 Mil. Therefore, GeneDx Holdings's EV-to-FCF for today is -72.26.
The historical rank and industry rank for GeneDx Holdings's EV-to-FCF or its related term are showing as below:
WGS'
s EV-to-FCF Range Over the Past 10 Years
Min: -235.54 Med: -1.13 Max: 4727.01
Current: -72.26
During the past 7 years, the highest EV-to-FCF of GeneDx Holdings was 4727.01. The lowest was -235.54. And the median was -1.13.
WGS's EV-to-FCF is ranked worse than 100% of 97
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.6
vs WGS: -72.26
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
GeneDx Holdings's PE Ratio (TTM) for today is calculated as:
GeneDx Holdings's share price for today is $69.82.
GeneDx Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.680.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
GeneDx Holdings EV-to-FCF Related Terms
GeneDx Holdings EV-to-FCF Historical Data
* Premium members only.
The historical data trend for GeneDx Holdings's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, GeneDx Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneDx Holdings EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GeneDx Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where GeneDx Holdings's EV-to-FCF falls into.
GeneDx Holdings's current Enterprise Value is $2,070.3 Mil.
GeneDx Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-28.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GeneDx Holdings (WGS) has a EV-to-FCF of -72.26 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on GeneDx Holdings and its competitors. According to the industry distribution chart, GeneDx Holdings ranks #999999 out of 97 companies in the Medical Diagnostics & Research industry.
Is GeneDx Holdings' EV-to-FCF too high?
GeneDx Holdings' current EV-to-FCF is -72.26. Based on the distribution chart, GeneDx Holdings ranks #999999 out of 97 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, GeneDx Holdings has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GeneDx Holdings' EV-to-FCF compare to NEO and PSNL?
According to the Medical Diagnostics & Research industry distribution chart, GeneDx Holdings ranks #999999 out of 97 companies for EV-to-FCF. This places GeneDx Holdings in the lower half of its industry. The industry median EV-to-FCF is 22.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.60, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on GeneDx Holdings and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneDx Holdings's current EV-to-FCF is -72.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneDx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GeneDx Holdings (WGS) is currently considered Fairly Valued. The stock's GF Value™ is $71.20, compared to a current price of $69.82 — trading 1.9% below its estimated fair value. The current EV-to-FCF is -72.26. GeneDx Holdings' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For GeneDx Holdings (WGS), the current EV-to-FCF is -72.26 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneDx Holdings (WGS) Overvalued in 2026?
Based on GuruFocus' analysis, GeneDx Holdings stock appears to be undervalued.
The current stock price of $69.82 is trading 1.9% below its estimated GF Value™ of $71.20.
GuruFocus considers GeneDx Holdings to be Fairly Valued.
Key valuation signals for WGS:
EV-to-FCF: -72.26
GF Value™: $71.20 vs. price of $69.82 (1.9% below fair value)
No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
60GF Score
Get the complete analysis for WGS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WGS has been successfully added to your 
